C07K9/00

High purity oritavancin and method of producing same

Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.

ANTIBODY SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
20200377553 · 2020-12-03 ·

The present application provides stable peptide-based antibody capture agents and methods of use as detection and diagnosis agents. The application further provides methods of manufacturing antibody capture agents using iterative on-bead in situ click chemistry.

ANTIBODY SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
20200377553 · 2020-12-03 ·

The present application provides stable peptide-based antibody capture agents and methods of use as detection and diagnosis agents. The application further provides methods of manufacturing antibody capture agents using iterative on-bead in situ click chemistry.

GRP78-DERIVED PEPTIDE FOR IDENTIFYING HIGH-EFFICIENCY STEM CELLS

The present invention relates to a GRP78-derived peptide for screening highly efficient stem cells and the use thereof, and more particularly, to screening highly efficient stem cells using, as a marker, a GRP78-derived peptide capable of binding to the binding domain of GRP78 protein on the cell surface. According to the present invention, the GRP78-derived peptide comprising only a specific amino acid sequence capable of recognizing highly efficient stem cells, among the amino acid sequence of GRP78, makes it possible to screen only non-senescent young stem cells. In addition, when stem cells are treated with the GRP78-derived peptide or the GRP78-derived peptide is introduced into stem cells, the efficiency of the stem cells can be increased. Thus, the GRP78-derived peptide is useful for the production of stem cell therapy products having excellent efficacy.

Hemiasterlin derivatives for conjugation and therapy
10844090 · 2020-11-24 · ·

Provided herein are hemiasterlin derivatives, conjugates thereof, compositions comprising the derivatives or conjugates thereof, methods of producing the derivatives and conjugates thereof, and methods of using the derivatives, conjugates, and compositions for the treatment of cell proliferation. The derivatives, conjugates, and compositions are useful in methods of treatment and prevention of cell proliferation and cancer, methods of detection of cell proliferation and cancer, and methods of diagnosis of cell proliferation and cancer. In an embodiment, the hemiasterlin derivatives are according to Formula 1000: ##STR00001##
or a pharmaceutically acceptable salt, solvate, or tautomer thereof, wherein Ar, L, W.sup.1, W.sup.4, W.sup.5, SG, and R are as described herein.

ANTIBIOTIC-GRAFTED ALUMINA CERAMIC MATRIX
20200353128 · 2020-11-12 · ·

The object of the invention is a porous alumina ceramic matrix grafted with an antibiotic, in particular vancoymicin, as well as its use in therapy. The invention also relates to a prosthesis or an implant using this matrix. The invention also relates to a method for preparing a matrix according to the invention.

Chimeric Molecule for Targeting c-Myc in Cells
20200354411 · 2020-11-12 ·

Disclosed herein are chimeric fusion proteins comprising a c-Myc inhibitor fused to genetically modified Pseudomonas Aeroginosa Exotoxin A (tPE), said fusion proteins being capable of penetrating a nucleus of a cell and inhibiting c-Myc activity within the nucleus. Also disclosed herein are pharmaceutical compositions comprising chimeric fusion proteins, methods of delivering, methods of preparing, methods of treating and uses of chimeric fusion proteins.

Chimeric Molecule for Targeting c-Myc in Cells
20200354411 · 2020-11-12 ·

Disclosed herein are chimeric fusion proteins comprising a c-Myc inhibitor fused to genetically modified Pseudomonas Aeroginosa Exotoxin A (tPE), said fusion proteins being capable of penetrating a nucleus of a cell and inhibiting c-Myc activity within the nucleus. Also disclosed herein are pharmaceutical compositions comprising chimeric fusion proteins, methods of delivering, methods of preparing, methods of treating and uses of chimeric fusion proteins.

ROUNDABOUT (ROBO) RECEPTOR INHIBITORS AND USES THEREOF

The present invention, in some embodiments thereof, relates to inhibitory compositions binding to the ectodomain of a Roundabout (Robo) receptor and to the use of same for downregulating Robo-mediated signaling. In particular, the present invention provides moieties that bind to and prevent dimerization of an Ig-like Robo receptor ectodomain, thereby inhibiting Robo receptor activity.

ROUNDABOUT (ROBO) RECEPTOR INHIBITORS AND USES THEREOF

The present invention, in some embodiments thereof, relates to inhibitory compositions binding to the ectodomain of a Roundabout (Robo) receptor and to the use of same for downregulating Robo-mediated signaling. In particular, the present invention provides moieties that bind to and prevent dimerization of an Ig-like Robo receptor ectodomain, thereby inhibiting Robo receptor activity.